Insmed Incorporated (INSM)
Nasdaq: INSM · Pharmaceutical Preparations · Bridgewater, NJ · filing with the SEC since 2000
Who owns Insmed Incorporated
As filed with the SECHolders of 5% or more
3
Fmr LLC holds 7.4% of COMMON STOCK, as its SCHEDULE 13G/A filed Aug 6, 2026 says.
Directors and officers
16
report now, of 28 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 6.1% in May 6, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jan 21, 2026 · Common Stock · 5.1% in Jul 17, 2025
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
JPMorgan Chase & Co.
SCHEDULE 13G/A · filed Jul 22, 2026 · Common stock, par value $0.01 per share · reported falling below 5%, from 10.8% in Sep 4, 2025
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed Nov 14, 2025 · COMMON STOCK · reported falling below 5%, from 5.9% in Aug 14, 2025
Darwin Global Management, Ltd.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.01 per share · reported falling below 5%, from 7.8% in May 15, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 10.2% in Jan 8, 2025
What INSM reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Adrestia Therapeutics Ltd
A company bought · acquisition, asset acquisition · owns, named in the 10-K filed Feb 19, 2026
Motus Biosciences, Inc.
A company bought · acquisition · owns, named in the 10-K filed Feb 19, 2026
Vertuis Bio, Inc.
A company bought · acquisition, asset acquisition · owns, named in the 10-K filed Feb 19, 2026
13 subsidiaries in 9 countries, from the list filed with the 10-K filed Feb 19, 2026.
Insider tradesForm 4
169sales
0purchases
130sales on a scheduled plan
10people selling
$167Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 20, 2025 to Oct 20, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 20, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window10 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Adsett Roger | Chief Operating Officer | 10 | $48.3M | 3 | 0 | $0 |
| Lewis William | Chair and CEO | 74 | $32.8M | 68 | 0 | $0 |
| Flammer Martina M.D. | Chief Medical Officer | 40 | $23.3M | 40 | 0 | $0 |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer | 9 | $21.1M | 5 | 0 | $0 |
| Lee Leo | director | 5 | $14.7M | 0 | 0 | $0 |
| Smith Michael Alexander | Chief Legal Officer | 20 | $14.0M | 14 | 0 | $0 |
| Sharoky Melvin Md | director | 2 | $4.7M | 0 | 0 | $0 |
| Brennan David R | director | 1 | $3.1M | 0 | 0 | $0 |
| Anderson Elizabeth M | director | 2 | $3.0M | 0 | 0 | $0 |
| Bonstein Sara | Chief Financial Officer | 6 | $2.1M | 0 | 0 | $0 |